Please provide your email address to receive an email when new articles are posted on . Poxel SA announced positive results for the phase 2a trial of PXL770 for the treatment of nonalcoholic ...

Credit: Shutterstock. PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. The Food and Drug Administration (FDA) has granted Fast Track ...

Nephrodi Therapeutics Inc. has entered an agreement with The McQuade Center for Strategic Research and Development LLC (MSRD), a member of the Otsuka family of pharmaceutical companies, to collaborate ...

Biolexis Therapeutics Inc. is working on developing orally available, small-molecule AMPK activators that have been found to stimulate AMPK activity as well as dose-dependently enhance glucose uptake ...

The liver plays a central role in maintaining systemic energy homeostasis during fasting by mobilizing lipid reserves, a process often accompanied by transient hepatic steatosis. Dimethylarginine ...